{"entity":{"id":"partner","kind":"trial","name":"PARTNER","aka":["PARTNER trial","NCT03150576"],"tldr":"Adding olaparib to this neoadjuvant chemotherapy schedule did not improve response or survival in germline-BRCA-wild-type TNBC.","summary":"The registry lists NCT03150576 as recruiting, last updated 2022-11-14. Enrolment is 780 planned participants, an estimate. Interventions: Olaparib, Paclitaxel and Carboplatin. Primary measures include Stage 1 - Number of participants with treatment-related adverse events as assessed by NCI CTCAE v4.03.; Stage 2 - pCR rate and completion rate of Olaparib treatment as per protocol.. No results are posted in the registry; this does not exclude separate publications. The 2024 germline-BRCA-wild-type randomised cohort included 559 participants. Pathological complete response was 51% versus 52% (p=0.753); three-year event-free survival was 80% versus 79% (p>0.9), and overall survival was 90% versus 87.2% (p=0.8). The separate 2025 germline-BRCA-positive cohort reported no pCR improvement (64.1% versus 69.8%, p=0.59), but estimated three-year EFS of 96.4% versus 80.1% and OS of 100% versus 88.2% (both p=0.04). The authors state that the result needs confirmation in larger trials. This is not a positive result in the wild-type population.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"Nature 2024 (DOI)","url":"https://doi.org/10.1038/s41586-024-07384-2"},{"label":"University of Cambridge news release","url":"https://www.cam.ac.uk/research/news/new-approach-to-treating-aggressive-breast-cancers-shows-significant-improvement-in-survival"},{"label":"Be Part of Research record","url":"https://bepartofresearch.nihr.ac.uk/trial-details/trial-detail?trialId=NCT03150576"},{"label":"PARTNER wild-type primary paper","url":"https://doi.org/10.1038/s41586-024-07384-2"},{"label":"Separate germline-BRCA cohort","url":"https://doi.org/10.1038/s41467-025-59151-0"},{"label":"ClinicalTrials.gov NCT03150576","url":"https://clinicaltrials.gov/study/NCT03150576"}],"tags":["uk","breast","neoadjuvant"],"related":[],"cancers":["tnbc","tnbc-early"],"sections":[],"technologies":["parp-inhibitor","platinum","cytotoxic-chemotherapy"],"targets":["brca","parp"],"drugs":["olaparib","carboplatin","paclitaxel"],"companies":[],"institutions":["addenbrookes-cambridge","cruk-cambridge-centre"],"pathways":[],"terms":["pcr","gbrca-mutation"],"trials":["phoenix","brightness","keynote-522"],"people":["jean-abraham"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Registry facts (24 September 2026): randomised three-stage phase 2/3 (NCT03150576) of olaparib added to neoadjuvant paclitaxel and carboplatin in triple-negative or germline BRCA breast cancer, sponsored by Cambridge University Hospitals with AstraZeneca and Cancer Research UK; 780 patients estimated; stage 3 primary endpoint pathological complete response by central review; status recruiting; 30 UK sites from Ayr and Kilmarnock to Swansea, Cardiff, Cambridge, Oxford, University College London Hospital and the Royal Free."],"nct":"NCT03150576","phase":"2/3","setting":"Randomised, Phase II/III, 3 Stage Trial to Evaluate the Safety and Efficacy of the Addition of Olaparib to Platinum-based Neoadjuvant Chemotherapy in Breast Cancer Patients With TNBC and/or gBRCA.","sponsor":"Cambridge University Hospitals NHS Foundation Trust","participation":[{"nct":"NCT03150576","source":"https://clinicaltrials.gov/study/NCT03150576","fetchedAt":"2026-10-07T16:52:57.726Z","studySha256":"242f03cd17c2309fba66975e81bfec24de338b9fd9780a1b92b8d04cd0e6f469","overallStatus":"RECRUITING","lastUpdatePosted":"2022-11-14","leadSponsor":"Cambridge University Hospitals NHS Foundation Trust","collaboratorCount":2,"minimumAge":"16 Years","maximumAge":"70 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":780,"enrolmentType":"ESTIMATED","siteCount":30,"recruitingSiteCount":30,"countries":["United Kingdom"]}],"result":"Germline-BRCA-wild-type cohort (Nature 2024): no pCR, EFS or OS improvement. Separate germline-BRCA cohort (Nature Communications 2025): primary pCR endpoint not improved; three-year survival signal needs confirmation.","started":"2016-05","yearReported":2024,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/partner/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"institution":[{"id":"addenbrookes-cambridge","kind":"institution","name":"Addenbrooke's Hospital, Cambridge University Hospitals","route":"/institutions/addenbrookes-cambridge/"},{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/"}],"term":[{"id":"gbrca-mutation","kind":"term","name":"Germline BRCA mutation (gBRCA)","route":"/terms/gbrca-mutation/"},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/"},{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}],"trial":[{"id":"brightness","kind":"trial","name":"BrighTNess","route":"/trials/brightness/"},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/"},{"id":"phoenix","kind":"trial","name":"PHOENIX DDR/Anti-PD-L1","route":"/trials/phoenix/"}],"person":[{"id":"jean-abraham","kind":"person","name":"Jean Abraham","route":"/people/jean-abraham/"}]}}